Zolpimist is a safe and a very effective drug equal to or even better than Ambien.
Ambien has gross revenue of several Billion dollars since it was first marketed and several hundred million dollars in revenue every year.
100 million dollars per year for Zolpimist in terms of revenue should be the absolute minimum target
as Zolpimist if promoted properly can bring in a lot more revenue than 100 million dollars per year but since there is no advertising or promotion of it that is why it has not been doing that to this point in time.
When does the Zolpimist re-launch start and what specifically are they doing to re-launch it?
HITK shareholders should want to know this as well as NVDL shareholders.